AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05375357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of L-PRF on the donor area
Description: After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF
Study NCT05375357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary intention healing of the donor area
Description: After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
Study NCT05377398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-intervention for substance use
Description: The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
Study NCT06138678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta-burst stimulation)
Description: The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study NCT06138678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS (intermittent theta-burst stimulation)
Description: The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study NCT05006170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT 20 mg
Description: Give 2 tabs of MYLTEGA DT (10mg) PO once daily
Study NCT05006170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT 25 mg
Description: Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
Study NCT06082180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic central neck dissection
Description: prophylactic central neck dissection was performed for the ipsilateral lesion
Study NCT06025955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive non- surgical therapy
Description: hand and ultrasonic instrumentation will be done
Study NCT06025955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: flap surgery will be done
Study NCT04444154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
Study NCT04444154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group with active participation
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Specified dose on specified days
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days
Study NCT04444154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group with video and quizz
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
Study NCT05622981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Age-specific educational materials and monitoring
Description: Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
Study NCT05386160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection of Ranibizumab；
Study NCT05386160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Phacoemulsification
Study NCT04920565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion with polymyxin B
Description: polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
Study NCT05255354 — intervention group
Intervention type: DEVICE
Intervention: ClonoSEQ
Description: Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
Study NCT05730088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
Study NCT05730088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application (Creating a WhatsApp group):
Description: A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
Study NCT05730088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone interview:
Description: Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
Study NCT06471231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min
Description: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure >65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
Study NCT06471231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min
Description: the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential current stimulation (100 Hz frequency)
Description: The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential current stimulation (0-100 Hz frequency)
Description: The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: behavioural therapy
Description: The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy.
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioural therapy
Description: The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy.
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise program
Description: Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training.
Study NCT04710654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training.
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Specified dose on specified days
Study NCT05144854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Specified dose on specified days
Study NCT06141798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Number of weekly hemodialysis treatment
Study NCT04563026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 30 mg
Description: IV infusion
Study NCT04563026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 90 mg
Description: IV infusion
Study NCT04563026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Standard of Care (SOC)
Description: IV infusion
Study NCT05117073 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASCITIC FLUID CULTURE
Description: Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
Study NCT05498831 — intervention group
Intervention type: OTHER
Intervention: Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse
Description: Pain will be assessed using a numerical scale
Study NCT06568640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superselective adrenal arterial embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
Study NCT06568965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-stress & happy gut powder-U001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days
Study NCT06568965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress & Happy Gut powder-I001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days
Study NCT06568965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Powder 001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days
Study NCT05652816 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Split-thickness skin graft
Description: Transplantation of autologous skin to burn area
Study NCT05652816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artificial skin graft
Description: Decellularized amnion membrane formed into 3-D matrix
Study NCT05652816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artificial skin graft co-culture
Description: Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
Study NCT06540326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome (II)
Description: irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
Study NCT06540326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
Study NCT06540326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Study NCT06540326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Study NCT04586569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Interactive Relational Agent (PIRA)
Description: The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
Study NCT05706454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramatroban
Description: Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days.
Study NCT05706454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally twice a day
Study NCT05761015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic program including intermittent drug intake and multimodal rehabilitation program
Description: The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age >65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.
Study NCT06540755 — intervention group
Intervention type: GENETIC
Intervention: genetic polymorphism analysis
Description: Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
Study NCT05001373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Core-g28v2 60mer mRNA Vaccine
Description: 100µg, Intramuscularly
Study NCT05001373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer mRNA Vaccine
Description: 100µg, Intramuscularly
Study NCT06240572 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06272448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation...), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
Study NCT04318002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Description: 3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
Study NCT05019716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT05019716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET-CT
Study NCT05019716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05019716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT06283771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated socks to be developed with wearable technology
Description: The study group will wear heated socks to be developed with wearable technology
Study NCT06466187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08052666
Description: Given into the vein (IV; intravenously)